CSL: The Dip Is the Opportunity

CSL: The Dip Is the Opportunity

Most people look at CSL's stock chart right now and see a problem. Down 35% from its highs, margins cut in half, and a company in the middle of its biggest restructuring in decades. I look at the same chart and see a good entry point.

The business: explained simply

CSL pays people to donate plasma, puts it through a complex manufacturing process, and turns it into life-saving medicines for patients with rare diseases people with immune deficiencies, bleeding disorders, and neurological conditions who have no alternative treatment. There is no substitute. You cannot engineer your way around the need for human plasma.

CSL runs three businesses. Behring is the core plasma therapies and gene therapy generating over $10 billion a year. Seqirus makes flu vaccines for governments. Vifor covers iron deficiency and kidney disease.

Behring is the moat, and that moat is built on something simple but almost impossible to copy 230+ plasma collection centres globally, representing decades of accumulated advantage. CSL holds 27–30% of the global plasma market. Its nearest rival, Grifols, has spent years trying to close that gap and hasn't. It's a physical and operational advantage that gets harder to replicate every year

What happened: and why the market got it wrong

FY2025 results were strong. Net profit rose 14% to US$3.3 billion and $15.6 billion in revenue. Then CSL announced it would cut 3,000 jobs and close 22 plasma centres. The stock dropped 17% in a single session, wiping A$20 billion in market value. At the October annual general meeting, management lowered their own profit expectations for the year ahead. The market didn't like it and selling resumed causing margins to fall from 18% to 9.1%.

The footnote

The $700–770 million in restructuring charges land almost entirely in 2026. They are one-off severance costs, asset write-downs, and the exit from the mRNA vaccine partnership that never scaled into a meaningful revenue stream. In return, CSL expects $500–550 million in annual savings from 2027 onwards. That's not a business cutting costs to survive. That's a sign of a business experiencing short-term decline to come out more profitable.

Remove the one-offs and the underlying business is still growing, cash generative, and dominant. CSL also launched a $750 million share buyback management putting their own capital into the stock at these prices is a signal worth paying attention to.

Where CSL goes from here

Global demand for immunoglobulin therapies is forecast to grow 30% by 2030, requiring plasma collections to grow at 8% per year just to keep pace. More patients are being diagnosed with rare diseases. More countries are funding immunoglobulin treatment. The market is growing faster than supply can follow which means CSL's network becomes more valuable every year, not less.

Gene therapy adds optionality. Hemgenix, CSL's haemophilia B gene therapy, published strong five-year durability data in late 2025. Clinical programs in sickle cell disease and cardiovascular conditions are progressing. None of these are priced into a stock trading at 18.7x earnings.

Seqirus is a profitable, globally relevant flu vaccine business that's currently overshadowed by the restructuring noise around plasma and Vifor. When the demerger proceeds, the market will finally have to price it on its own and that gap between hidden and recognised value could be meaningful.

Catalysts

The bar is low. A clean second half of 2026 result, savings arriving on schedule, and China showing any sign of stabilising is all the market needs to start repricing this stock.

Risks

The biggest question mark is Vifor. It was an expensive acquisition, and if competition in nephrology proves more aggressive than expected and the acquisition fails to earn its cost of capital, the earnings recovery gets pushed out or doesn't happen at all. Execution risk is also real closing 22 centres without disrupting a 9-12 month manufacturing cycle is difficult. Currency is a factor too, since CSL earns mostly in USD but reports in AUD.

Fair value

CSL is cheap by almost every measure. The market is currently paying 18.7x earnings for a business that has historically traded at 28–30x and sits in a sector where its peers average 36x. That gap exists because FY2026 earnings are distorted by one-off restructuring charges not because the underlying business has deteriorated.

When the one-off costs are gone and $500–550 million in annual savings are running through the business.. Applying a conservative 25x multiple to normalised earnings a discount to both peers and CSL's own history gives a fair value of AU$220–250. At current prices around AU$142, 11/16 analysts agree, with a consensus target of AU$237–244.

The math just assumes the one-off costs don't repeat which is exactly what they are designed not to do.

The bottom line

CSL is messier than it was at AU$300. The balance sheet is heavier and the near-term earnings story is clouded. But the plasma network is still irreplaceable, immunoglobulin demand is still growing, and the selloff is largely explained by costs that won't repeat.

For a long-term investor willing to look through twelve months of noise, CSL at around AU$142 is a high-quality business at a discount-quality price.

The dip is the opportunity, not the warning sign.